CoChat
Sign Up
Cited by 89Pancreatitis Pathology and TreatmentDiabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

Thomsen, Reimar Wernich, Pedersen, Lars, Møller, Niels, Kahlert, Johnny, Beck-Nielsen, Henning, Sørensen, Henrik Toft·2015·Diabetes Care
DOI 10.2337/dc13-2983
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To investigate whether the use of incretin-based drugs (GLP-1 receptor agonists and dipeptidyl peptidase 4 [DPP4] inhibitors) is associated with acute pancreatitis. RESEARCH DESIGN AND METHODS: The study was a nationwide population-based case-control study using medical databases in Denmark. Participants were 12,868 patients with a first-time hospitalization for acute pancreatitis between 2005 and 2012 and a population of 128,680 matched control subjects. The main outcome measure was the odds ratio (OR) for acute pancreatitis associated with different antihyperglycemic drugs. We adjusted for history of gallstones, alcoholism, obesity, and other pancreatitis-associated comorbidities and medications. RESULTS: A total of 89 pancreatitis patients (0.69%) and 684 control subjects (0.53%) were ever users of incretins. The crude OR for acute pancreatitis among incretin users was 1.36 (95% CI 1.08–1.69), while it was 1.44 (95% CI 1.34–1.54) among users of other antihyperglycemic drugs. After confounder adjustment, the risk of acute pancreatitis was not increased among incretin users (OR 0.95 [95% CI 0.75–1.21]), including DPP4 inhibitor users (OR 1.04 [95% CI 0.80–1.37]) or GLP-1 receptor agonist users (OR 0.82 [95% CI 0.54–1.23]), or among nonincretin antihyperglycemic drug users (OR 1.05 [95% CI 0.98–1.13]), compared with nonusers of any antihyperglycemic drugs. Findings were similar in current versus ever drug users and in patients with pancreatitis risk factors. The adjusted OR comparing incretin-based therapy with other antihyperglycemic therapy internally while also adjusting for diabetes duration and complications was 0.97 (95% CI 0.76–1.23). CONCLUSIONS: Our findings suggest that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis.

Integrity signals

Registry

Crossref · 10.2337/dc13-2983

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T.
Affiliations
  • Aarhus University Hospital (DK)
  • The Danish Centre for Strategic Research in Type 2 Diabetes, Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark
Corresponding author
Thomsen, Reimar Wernich
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2015-01-29
Volume
38
Issue
6
Pages
1089-1098
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc13-2983
OpenAlex
W1969969418
Cited by
89
References
32
Citations by year
2026: 6 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 6 · 2016: 24 · 2015: 11
FWCI
16.78
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
acute pancreatitis, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, antidiabetic drugs, drug safety, diabetes mellitus
MeSH terms
Acute Disease, Adolescent, Adult, Aged, Denmark, Diabetes Mellitus, Type 2, Epidemiologic Methods, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Databases, Factual, Glucagon-Like Peptide 1, Incretins, Dipeptidyl-Peptidase IV Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review